全文获取类型
收费全文 | 35650篇 |
免费 | 2519篇 |
国内免费 | 746篇 |
专业分类
耳鼻咽喉 | 153篇 |
儿科学 | 427篇 |
妇产科学 | 408篇 |
基础医学 | 2092篇 |
口腔科学 | 202篇 |
临床医学 | 2914篇 |
内科学 | 4160篇 |
皮肤病学 | 525篇 |
神经病学 | 1310篇 |
特种医学 | 662篇 |
外国民族医学 | 2篇 |
外科学 | 1770篇 |
综合类 | 4368篇 |
现状与发展 | 3篇 |
预防医学 | 4166篇 |
眼科学 | 231篇 |
药学 | 11405篇 |
19篇 | |
中国医学 | 920篇 |
肿瘤学 | 3178篇 |
出版年
2024年 | 74篇 |
2023年 | 483篇 |
2022年 | 1183篇 |
2021年 | 1448篇 |
2020年 | 1232篇 |
2019年 | 1131篇 |
2018年 | 1097篇 |
2017年 | 1048篇 |
2016年 | 1131篇 |
2015年 | 1311篇 |
2014年 | 2735篇 |
2013年 | 3220篇 |
2012年 | 2555篇 |
2011年 | 2828篇 |
2010年 | 2065篇 |
2009年 | 1947篇 |
2008年 | 1934篇 |
2007年 | 1789篇 |
2006年 | 1495篇 |
2005年 | 1211篇 |
2004年 | 975篇 |
2003年 | 785篇 |
2002年 | 584篇 |
2001年 | 523篇 |
2000年 | 465篇 |
1999年 | 459篇 |
1998年 | 307篇 |
1997年 | 275篇 |
1996年 | 225篇 |
1995年 | 234篇 |
1994年 | 224篇 |
1993年 | 165篇 |
1992年 | 161篇 |
1991年 | 117篇 |
1990年 | 113篇 |
1989年 | 97篇 |
1988年 | 104篇 |
1987年 | 105篇 |
1986年 | 102篇 |
1985年 | 124篇 |
1984年 | 136篇 |
1983年 | 75篇 |
1982年 | 78篇 |
1981年 | 61篇 |
1980年 | 67篇 |
1979年 | 54篇 |
1978年 | 58篇 |
1977年 | 55篇 |
1976年 | 60篇 |
1975年 | 65篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
2015年中华医学会感染病学分会艾滋病学组发布了第三版《艾滋病诊疗指南》。新版指南强调抗病毒治疗时点前移:一旦成人确诊感染人类免疫缺陷病毒(HIV), 若无禁忌宜尽早启动抗HIV治疗。对于合并机会性感染的HIV感染者, 在感染控制、病情稳定后也应及早开始抗病毒治疗。尤其强调HIV合并结核患者在CD4阳性淋巴细胞数少于200/μL的情况下, 建议抗结核两周内即开始抗病毒治疗。在抗HIV治疗用药中, 淘汰了一些毒副作用大、依从性较差的药物, 如司他夫定、去羟肌苷、茚地那韦等, 优选抗病毒效力强、服药方便的组合, 如拉米夫定、替诺福韦、依非韦伦组合。对于HIV感染的婴幼儿, 亦主张及早抗HIV治疗。对于五岁以内的幼儿, 主张确诊后即启动抗病毒治疗。对于HIV感染的孕产妇, 建议尽快予以全程、联合抗HIV治疗, 寓防于治。 相似文献
12.
13.
14.
《Biomaterials》2015
Podophyllotoxin (PPT) exhibited significant activity against P-glycoprotein mediated multidrug resistant (MDR) tumor cell lines; however, due to its poor solubility and high toxicity, PPT cannot be dosed systemically, preventing its clinical use for MDR cancer. We developed a nanoparticle dosage form of PPT by covalently conjugating PPT and polyethylene glycol (PEG) with acetylated carboxymethyl cellulose (CMC-Ac) using one-pot esterification chemistry. The polymer conjugates self-assembled into nanoparticles (NPs) of variable sizes (20–120 nm) depending on the PPT-to-PEG molar ratio (2–20). The conjugate with a low PPT/PEG molar ratio of 2 yielded NPs with a mean diameter of 20 nm and released PPT at ∼5%/day in serum, while conjugates with increased PPT/PEG ratios (5 and 20) produced bigger particles (30 nm and 120 nm respectively) that displayed slower drug release (∼2.5%/day and ∼1%/day respectively). The 20 nm particles exhibited 2- to 5-fold enhanced cell killing potency and 5- to 20-fold increased tumor delivery compared to the larger NPs. The biodistribution of the 20 nm PPT-NPs was highly selective to the tumor with 8-fold higher accumulation than all other examined tissues, while the larger PPT-NPs (30 and 120 nm) exhibited increased liver uptake. Within the tumor, >90% of the 20 nm PPT-NPs penetrated to the hypovascular core, while the larger particles were largely restricted in the hypervascular periphery. The 20 nm PPT-NPs displayed significantly improved efficacy against MDR tumors in mice compared to the larger PPT-NPs, native PPT and the standard taxane chemotherapies, with minimal toxicity. 相似文献
15.
16.
的 了解血流感染肺炎克雷伯菌中CRISPR-Cas系统的分布特征并分析其与毒力基因和耐药的关系。方法 收集非重复血流感染肺炎克雷伯菌248株,使用Vitek2-Compact全自动微生物分析系统进行菌株鉴定及药物敏感性分析,PCR检测CRISPR-Cas系统3个相关基因(CRISPR1、CRISPR2和cas1)、筛查6种常见高毒力荚膜血清型(K1、K2、K5、 K20、K54和K57)、12种毒力基因及检测13种耐药基因,用χ2检验比较携带有CRISPR-Cas系统菌株与不携带CRISPR-Cas系统菌株毒力及耐药差异。结果 CRISPR-Cas系统的检出率为29.8%(74/248);K1型是携带CRISPR-Cas系统肺炎克雷伯菌的主要荚膜血清型,占 28.4%(21/74);除kpn基因外,携带CRISPR-Cas系统菌株的毒力基因检出率均大于不携带CRISPR-Cas系统菌株,其中7种差异有统计学意义;除对氨苄西林耐药率达100%外,携带有CRISPR-Cas系统菌株的其他抗菌药物耐药率均小于不携带有CRISPR-Cas系统菌株,其中13种差异有统计学意义;携带CRISPR-Cas系统菌株的耐药基因阳性率小于不携带CRISPR-Cas系统的菌株,且blaKPC、blaSHV、qnrS基因差异有统计学意义。结论 高毒力荚膜血清型肺炎克雷伯菌中主要为K1型携带CRISPR-Cas系统,携带CRISPR-Cas系统的肺炎克雷伯菌相对于不携带CRISPR-Cas系统菌株的毒力基因阳性率高,耐药率低,耐药基因的阳性率低。CRISPR-Cas系统可能能降低耐药基因在肺炎克雷伯菌中的水平传播,尤其是在K1型肺炎克雷伯菌。 相似文献
17.
18.
《JACC: Cardiovascular Interventions》2022,15(7):741-750
ObjectivesThe aim of this study was to report 1-year clinical outcomes following commercial transcatheter left atrial appendage occlusion (LAAO) in the United States.BackgroundThe National Cardiovascular Data Registry LAAO Registry was initiated to meet a condition of Medicare coverage and allow the assessment of clinical outcomes. The 1-year rates of thromboembolic events after transcatheter LAAO in such a large cohort of “real-world” patients have not been previously reported.MethodsPatients entered into the National Cardiovascular Data Registry LAAO Registry for a Watchman procedure between January 1, 2016, and December 31, 2018, were included. The primary endpoint was ischemic stroke. Key secondary endpoints included the rate of ischemic stroke or systemic embolism, mortality, and major bleeding. Major bleeding was defined as any bleeding requiring hospitalization, and/or causing a decrease in hemoglobin level > 2g/dL, and/or requiring blood transfusion that was not hemorrhagic stroke. The Kaplan-Meier method was used for 1-year estimates of cumulative event rates.ResultsThe study population consisted of 36,681 patients. The mean age was 76.0 ± 8.1 years, the mean CHA2DS2-VASc score was 4.8 ± 1.5, and the mean HAS-BLED score was 3.0 ± 1.1. Prior stroke was present in 25.5%, clinically relevant bleeding in 69.5%, and intracranial bleeding in 11.9%. Median follow-up was 374 days (IQR: 212-425 days). The Kaplan-Meier–estimated 1-year rate of ischemic stroke was 1.53% (95% CI: 1.39%-1.69%), the rate of ischemic stroke or systemic embolism was 2.19% (95% CI: 2.01%-2.38%), and the rate of mortality was 8.52% (95% CI: 8.19%-8.87%). The 1-year estimated rate of major bleeding was 6.93% (95% CI: 6.65%-7.21%). Most bleeding events occurred between discharge and 45 days following the procedure.ConclusionsThis study characterizes important outcomes in a national cohort of patients undergoing transcatheter LAAO in the United States. Clinicians and patients can integrate these data in shared decision making when considering this therapy. 相似文献
19.
Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma
20.